Advanced Monitoring and Referral Strategies in Feline Diabetes: Evidence-Based Clinical Decision-Making

Introduction 

Feline diabetes mellitus (FDM) is a common endocrine disorder characterised by persistent hyperglycaemia due to insulin resistance and relative β-cell dysfunction. Effective management requires insulin therapy alongside continuous, trend-based monitoring and timely referral when treatment targets are not met¹. Advances in technology, including home glucose monitoring and continuous glucose monitoring systems (CGMS), enable veterinarians to detect glucose trends and optimise insulin therapy². Referral to an endocrinology specialist or advanced diagnostic centre is recommended when insulin resistance, comorbidities, or atypical presentations complicate management³. 

Monitoring: Beyond Single Measurements 

Single point-in-time blood glucose readings are often insufficient for cats because stress-induced hyperglycaemia can confound results¹. Trend-based monitoring through serial capillary blood glucose curves, home monitoring, or CGMS provides a more reliable assessment. CGMS allows detailed insight into diurnal glucose patterns, including postprandial hyperglycaemia and nocturnal hypoglycaemia, which can guide precise insulin dose adjustments². 

Decision Point: Selecting a Monitoring Strategy 

If a diabetic cat shows inconsistent glucose control or unexplained hypoglycaemia episodes, CGMS or structured home monitoring should be used to guide safe and precise insulin titration². 

 Clinical Applications of Monitoring 

Monitoring in feline diabetes allows clinicians to differentiate fasting hyperglycaemia from postprandial spikes and track glycaemic trends over time. Fructosamine measurement provides a 2–3 week integrated estimate of glycaemic control, which is particularly useful in cats prone to stress hyperglycaemia¹. Ambulatory glucose trends captured via CGMS enable adjustments to insulin timing and dosing, reducing the risk of hypoglycaemia and improving long-term outcomes². 

Decision Point: Therapy Adjustment 

If CGMS reveals recurrent postprandial hyperglycaemia or nocturnal hypoglycaemia, insulin type, timing, or dosage should be adjusted, with ongoing monitoring to assess response². 

Referral Considerations 

Referral is indicated when glycaemic control remains poor despite correct insulin administration and adherence. Cats requiring unusually high insulin doses may have underlying conditions such as hypersomatotropism, which can markedly impair insulin sensitivity.³ Comorbidities, including renal, hepatic, or cardiac disease, may further complicate management, necessitating specialist input. Persistent glycaemic instability despite optimisation of therapy warrants evaluation at an advanced diagnostic centre³. 

Decision Point: When to Refer 

If stable glycaemic targets are not achieved after 2–3 months of optimised therapy, referral for endocrine evaluation, including IGF-1 measurement or imaging for hypersomatotropism, should be considered³. 

 Integrating Technology in Feline Practice 

Combining home monitoring, CGMS, and laboratory assessments allows clinicians to make evidence-based, patient-specific decisions. Trend analysis guides insulin titration and distinguishes true glycaemic variability from stress-induced spikes^1,2. Additionally, technology supports owner education, improves adherence, and enhances long-term glycaemic control. 

Decision Point: Optimising Clinical Outcomes 

If trend-based monitoring shows consistent deviations from glycaemic targets, therapy adjustments should be guided by monitoring data rather than empiric insulin increases^1,2. 

Clinical Takeaways  

Feline diabetes management requires a combination of insulin therapy, structured monitoring, and timely referral. Single glucose readings are unreliable; trend-based monitoring via home measurements or CGMS provides actionable data. Persistent poor control despite therapy should prompt evaluation for insulin resistance, comorbidities, or hypersomatotropism. Integrating structured monitoring with technological tools improves clinical decision-making, therapy adjustments, and long-term outcomes. 

 References  

1. Taylor S, Cannon M, Church D, Fleeman L, Fracassi F, Gilor C, et al. iCatCare consensus guidelines on the diagnosis and management of diabetes mellitus in cats. J Feline Med Surg. 2025. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12612538/ 

2. Patras S, McMillan CJ, Snead ER, et al. Continuous glucose monitoring in diabetic cats: trends and clinical applications. Front Vet Sci. 2022;9:905929. Available from: https://www.frontiersin.org/articles/10.3389/fvets.2022.905929/full 

3. Galac S, van Bokhorst KL, Kooistra HS. Hypersomatotropism as a cause of insulin resistance in diabetic cats. J Vet Intern Med. 2021;35(2):767–776. Available from: https://pubmed.ncbi.nlm.nih.gov/33621385/